• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, October 24, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Fighting Osimertinib Resistance in Lung Cancer Treatment

Bioengineer by Bioengineer
November 27, 2023
in Cancer
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Lung cancer remains one of the leading causes of cancer-related deaths worldwide. Among its types, non-small cell lung cancer (NSCLC) constitutes approximately 85%, posing significant challenges for patients and healthcare professionals, especially due to its late-stage diagnosis and complex treatment processes. However, the last decade has witnessed transformative advancements in molecular biology and drug development, changing the grim outlook of lung cancer treatment. Central to this transformation has been the role of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs).

EGFR-TKIs have emerged as a beacon of hope, especially for patients with NSCLC harboring EGFR mutations. Among these, osimertinib, a third-generation EGFR-TKI, has gained prominence by targeting the EGFR’s T790M mutation, offering effective treatment options. Initially approved for patients with EGFR T790M mutations, osimertinib has now become the dominant first-line targeted therapy for the majority of EGFR mutant lung cancers.

The effectiveness of osimertinib in both first and second-line treatments is noteworthy. However, the emergence of resistance during treatment poses significant limitations to its long-term efficacy. Studies have shown that NSCLC patients typically develop resistance to osimertinib within an average of 19 months in first-line treatment and 11 months in second-line treatment. The mechanisms of resistance are complex and multifaceted, involving both EGFR-dependent and independent pathways.

Understanding and overcoming these resistance mechanisms present substantial challenges for both basic and clinical researchers. The C797S mutation in EGFR’s exon 20 is one of the most commonly known mutations leading to resistance against osimertinib treatment. Additionally, other mutations in exon 20 are also linked to resistance. The loss of the T790M mutation, a consequence of continuous use of third-generation EGFR-TKIs, also contributes to osimertinib resistance. Moreover, mutations in the L718 and G719 regions of EGFR’s exon 18 can also lead to resistance against osimertinib.

To overcome these resistance mechanisms, new treatment strategies are being developed, including the exploration of fourth-generation TKIs. Brigatinib, a fourth-generation TKI developed to overcome the C797S mutation, has shown promising therapeutic effects in NSCLC patients with this mutation.

Large-scale clinical trials, like the ORCHARD trial, are necessary to evaluate the effectiveness of various treatment options against these resistance mechanisms. Current treatment modalities also include chemotherapy and immunotherapy. Notably, immunotherapy agents like PD-1 and PD-L1 have opened new horizons in the treatment of EGFR mutation-driven NSCLC. Additionally, chimeric antigen receptor T cell (CAR-T) immunotherapy has emerged as a novel idea in NSCLC treatment, although its efficacy in patients with EGFR mutations needs further research and case studies.

As osimertinib continues to play a central role in the treatment of NSCLC with EGFR mutations, understanding resistance mechanisms and developing corresponding strategies is of utmost importance. Progress in this field continues to offer new hopes and opportunities in lung cancer treatment.

Reference

Li, Yufeng, et al. “Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer.” Cell Communication and Signaling 21.1 (2023): 71

Tags: brigatinibC797S mutationC797S/T790M mutationsCAR-T cell therapychemotherapyclinical studiesEGFR amplificationEGFR exon 18 mutationsEGFR exon 20 mutationsEGFR mutationsEGFR-TKIfourth generation TKIhealth researchimmunotherapyinnovations in cancer treatmentlung cancermolecular treatment methodsnon-small cell lung cancerNSCLCORCHARD trialosimertinib resistanceosimertinib treatmentPD-1PD-L1targeted cancer therapytyrosine kinase inhibitors
Share13Tweet8Share2ShareShareShare2

Related Posts

Silencing SOX2OT Lowers Lung Cancer Cell Aggressiveness

October 24, 2025

New Alliance Launches Clinical Trials of Targeted Therapies for Rare Adrenal Cancers

October 23, 2025

Illuminating Life: Rice Scientists Create Glowing Sensors to Monitor Cellular Changes in Real Time

October 23, 2025

Study Reveals Hidden Immune Defense Mechanism That Could Combat Cancer

October 23, 2025

POPULAR NEWS

  • Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission

    1278 shares
    Share 510 Tweet 319
  • Stinkbug Leg Organ Hosts Symbiotic Fungi That Protect Eggs from Parasitic Wasps

    308 shares
    Share 123 Tweet 77
  • ESMO 2025: mRNA COVID Vaccines Enhance Efficacy of Cancer Immunotherapy

    181 shares
    Share 72 Tweet 45
  • New Study Suggests ALS and MS May Stem from Common Environmental Factor

    132 shares
    Share 53 Tweet 33

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Health Workers’ Radiation Knowledge Influences Attitudes

Bat Flies’ Microbial Networks Vary by Host Specificity

Evaluating Solvents for Lycopene Recovery Efficiency

Subscribe to Blog via Email

Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm' to start subscribing.

Join 66 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.